Skip to main content

Table 2 Predictors of Chikungunya rheumatism issues in subjects ≥ 15 years of age (full model) in the TELECHIK study, La Réunion, 2007 to 2008

From: Predictors of Chikungunya rheumatism: a prognostic survey ancillary to the TELECHIK cohort study

Outcomes (versus recovery as reference)

Relapsing rheumatic musculoskeletal pain

Lingering rheumatic musculoskeletal pain

Determinants

N

CIR, %

Adjusted odds ratio

95% CI

P- value

N

CIR, %

Adjusted odds ratio

95% CI

P- value

Gender

    

0.536

    

0.562

Male

41

34.7

1

  

48

31.9

1

  

Female

70

32.4

0.78

0.34, 1.74

 

102

42.2

0.78

0.33, 1.82

 

Age

    

0.013

    

< 0.001

15 to 29 yrs

19

27.3

1

  

12

20.7

1

  

30 to 44 yrs

32

37.9

1.60

0.57, 4.51

 

28

30.4

1.64

0.51, 5.31

 

45 to 59 yrs

27

30.0

2.67

0.78 - 9.10

 

52

50.2

5.62

1.52, 20.79

 

≥ 60 yrs

33

36.3

9.20

2.31, 36.59

 

58

55.6

16.03

3.82, 67.13

 

Underlying comorbidity

    

0.667

    

0.555

None

56

32.8

1

  

62

32.5

1

  

Metabolic syndrome without rheumatic disorders*

35

31.8

1.45

0.45, 4.65

 

63

53.6

1.92

0.59, 6.24

 

Rheumatic disorders with or without metabolic syndrome**

6

33.5

1.67

0.20, 13.53

 

16

53.8

2.11

0.27, 16.26

 

Other conditions

12

44.7

2.02

0.62, 6.49

 

8

18.8

2.02

0.60, 6.81

 

Initial rheumatic involvement

    

0.008

    

0.001

Low to moderate

70

31.8

1

  

77

31.0

1

  

Severe

41

35.6

3.52

1.40, 8.87

 

73

50.0

5.43

1.95, 15.11

 

CHIKV-specific IgG titre (per one unit increase)

111

33.2

3.31

1.82, 5.99

< 0.001

150

38.3

5.72

2.74, 12.51

< 0.001

Exposure Score #

    

0.132

    

0.195

First quartile class (-2.526; -0.415)

21

32.3

1

  

32

38.7

1

  

Second quartile class (-0.400; 0.018)

27

31.9

0.60

0.20, 1.73

 

33

33.2

0.48

0.16, 1.42

 

Third quartile class (0.026; 0.432)

23

27.0

0.53

0.17, 1.70

 

35

41.7

0.70

0.22, 2.13

 

Fourth quartile class (0.433; 1.435)

25

38.3

2.09

0.57, 7.59

 

39

42.6

1.87

0.43, 7.97

 
  1. CIR, cumulative incidence rate; CHIKV, Chikungunya virus; N, number. All estimations and P-values are weighted by the sampling scheme. *Metabolic syndrome was defined by any of the following features: body mass index ≥ 30 kg/m2 , diabetes mellitus, arterial hypertension, or any type of dyslepidemia; **hip, knee or hand osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and psoriatic spondylarthritis and other types of rheumatic disorders, such as gout; coronary heart disease, asthma, chronic bronchitis, renal insufficiency, cancer; #exposure score build up with six covariates and two derivatives (eight components) including residence area, housing type, a first interaction term between the residence area and housing type, deciles of altitude, household size, history of recent Chikungunya-related picture in the neighbours, a second interaction term between the household size and history of Chikungunya, and last, the answer to the question: 'Is Chikungunya virus a mosquito-borne virus?'. All subjects had arthralgia or muscle pain at disease onset. Joint or muscle pain with at most two of the three following conditions: fever, six or more localizations of arthralgia, at least four other symptoms; fever and six or more localizations of arthralgia and at least four other symptoms.